Based on these preclinical studies, a clinical phase I/II study was published in 2019, showing that the infusion of the CXCR4 inhibitor plerifaxor was well tolerated as an adjunct to standard chemoirradiation with newly diagnosed glioblastoma and improved local control of tumor recurrences [27]. This evidence concerns the gene CXCR4 and glioblastoma.